isavuconazole and anidulafungin. Inoculum suspensions were prepared from 7 to 14 day cultures on potato carrot agar, by slightly scraping the surface of mature colonies with a sterile cotton swab wetted with sterile saline including Tween 40 (0.05%). The supernatants were adjusted spectrophotometrically at a wavelength of 530 nm to an optical density (OD) that ranged from 0.25 to 0.3 (2Â10 4 -7Â10 4 cfu/mL). 3 Microdilution plates were incubated at 308C for 48 h (plates with insufficient growth were incubated for 72 h) and read visually after agitation. 1 There are few published data available concerning the in vitro antifungal susceptibility with microdilution techniques of Alternaria species; 4,5 the largest collection included just 13 strains. 4 Reported MIC 50 and MIC 90 values of posaconazole, itraconazole and amphotericin B are comparable to our results. Among the azoles, fluconazole showed uniform low activities against Alternaria species in this and previous studies.
summarizes the results of all in vitro activities of the eight antifungal drugs. Both environmental and clinical Alternaria isolates showed an MIC range from 0.125 to 1 mg/L for amphotericin B. We found the widest range and the highest MICs for fluconazole (range 4-32 mg/L). Surprisingly, most isolates of A. infectoria and A. alternata had high MICs of voriconazole, although the environmental isolates of A. malorum (a non-human pathogenic species) had lower MICs. Isavuconazole had high MICs similar to voriconazole with complete inhibition endpoints exhibiting MIC 50 1 Severe deep infections are rare complications and optimal treatment is not known. 2 Various antifungal drugs have been used in the treatment of Alternaria infection, such as amphotericin B, flucytosine, fluconazole, miconazole and nystatin.
1 There are few published data available concerning the in vitro antifungal susceptibility with microdilution techniques of Alternaria species; 4,5 the largest collection included just 13 strains. 4 Reported MIC 50 and MIC 90 values of posaconazole, itraconazole and amphotericin B are comparable to our results. Among the azoles, fluconazole showed uniform low activities against Alternaria species in this and previous studies. 4, 5 Except one report involving 11 isolates, 5 itraconazole, voriconazole and posaconazole had good in vitro activity. Recently, the new azole isavuconazole was tested and generated MIC 50 and MIC 90 values of 1 mg/L. 6 We describe lower in vitro activities (MIC 90 4 mg/L) of voriconazole and isavuconazole. There was no isolate with an MIC of isavuconazole .4 mg/L, suggesting a potential role in therapy and prophylaxis if adequate drug levels are achieved at the site of infection. In contrast, posaconazole demonstrated potent activity (MIC 90 0.25 mg/L) against all clinical and environmental isolates of Alternaria, but it remains to be confirmed that high enough drug levels can be reached at a remote site of infection. Isavuconazole has not been used clinically for Alternaria infections, but posaconazole was the only clinically active antifungal drug in the treatment of a severe invasive Alternaria infection in an immunocompetent patient. 1 In the present study, the antifungal activities of posaconazole and anidulafungin were superior against clinical isolates of A. infectoria. Furthermore, we demonstrated better activity of anidulafungin compared with that of caspofungin, but it is not known whether these in vitro differences are clinically significant. In conclusion, posaconazole and anidulafungin demonstrated the highest in vitro antifungal activity against Alternaria species, including those clinical and environmental isolates that had higher MICs of voriconazole and isavuconazole; their clinical effectiveness in the treatment of Alternaria infection remains to be determined.
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Keywords: carbapenems, colistin, ventriculoperitoneal shunts *Corresponding author. Tel: þ1-901-448-5770; Fax: þ1-901-448-5940; E-mail: kcleveland@utmem.edu Sir, Pseudomonas ventriculitis is an unusual infection associated with neurosurgical procedures or trauma. 1 Treatment is usually with a combination of an intravenous (iv) anti-pseudomonal b-lactam and an aminoglycoside, administered iv and/or intrathecally (it). 1 Ceftazidime has been the b-lactam used most frequently for pseudomonal CNS infections. 2 Meropenem is the only carbapenem approved for CNS infections. The carbapenem class is the class of b-lactams most likely to encounter emerging antimicrobial resistance when used for treatment of Pseudomonas aeruginosa infections. 3 We recently treated a patient with P. aeruginosa ventriculitis where the isolate developed resistance to all b-lactams except doripenem. A combination of doripenem and tobramycin (iv and it) was used with successful eradication of infection.
Case
An adult quadriparetic patient was transferred to our hospital for management of an infected ventriculoperitoneal (VP) shunt. VP shunting was first performed on this patient at the age of 27 months for congenital type 1 Arnold-Chiari malformation with a meningomyelocoele. Three weeks prior to admission at our hospital, headache and fever developed and the patient was hospitalized at another facility. Tracheostomy site was noted to have eroded in close proximity to the VP shunt and examination of the CSF showed evidence of bacterial meningitis. Culture of CSF grew P. aeruginosa, susceptible to imipenem, meropenem, ceftazidime, cefepime, piperacillin/ tazobactam, tobramycin and ciprofloxacin (Kirby-Bauer disc diffusion method). iv ceftazidime, meropenem and tobramycin were given and the patient was transferred to our hospital.
Computed tomography (CT) of the abdomen showed no abscess or fluid collection. Cultures of the blood and urine were negative. Chest radiograph did not reveal infiltrates. The white blood cell count was 19100 cells/mm 3 . Measurements of renal and hepatic function were normal. CT of the head with iv contrast showed right parieto-occipital VP shunt and no hydrocephalus.
Meropenem (1 g iv every 8 h) and tobramycin (5 mg/kg iv daily) were continued. On the third day of hospitalization, the VP shunt was removed and an external ventricular device (EVD) was placed. Cultures of the VP shunt and wound grew P. aeruginosa susceptible to tobramycin, amikacin and ciprofloxacin, but resistant to cefepime, ceftazidime, imipenem, piperacillin/tazobactam and aztreonam (MicroScan, Dade Behring Inc., Sacramento, CA, USA).
Two days later, culture of CSF obtained from the EVD grew P. aeruginosa with susceptibilities identical to those previously reported. Additional testing of the isolate showed resistance to meropenem with an MIC of .8 mg/L and susceptibility to doripenem with an MIC of 1.5 mg/L (Etest, AB bioMerieux, Durham, NC, USA) and colistin.
Meropenem was discontinued and doripenem (1 g iv infused over 60 min every 8 h) and tobramycin (10 mg it daily) were started. iv tobramycin was continued. Ciprofloxacin was not used as the patient had a history of anaphylaxis following administration of ofloxacin.
Additional cultures of CSF obtained 3, 5, 6, 7 and 8 days after VP shunt removal grew P. aeruginosa with identical antimicrobial susceptibilities. Magnetic resonance imaging of the head with gadolinium contrast showed no evidence of an intracranial abscess or fluid collection.
CSF cultures obtained 9, 12, 13, 14 and 15 days after VP shunt removal did not grow any organisms. Fourteen days of doripenem and it tobramycin and 21 days of iv tobramycin were administered. The patient experienced no adverse effect attributed to the antimicrobials (e.g. myoclonus, seizure or renal dysfunction). Audiometry was not performed.
Eighteen days after removal of the VP shunt, a left VP shunt was placed and the EVD was removed. One month after placement of the new VP shunt, the patient remained stable with no evidence of recurrent ventriculitis.
Usual therapy of VP shunt infection includes removal of the infected shunt and administration of iv and/or it antibiotics. 4 iv and/or it colistin has been used successfully in the management of CNS infections due to multiresistant Gram-negative organisms. 5 Use of colistin in our patient was considered and would likely have been used had the patient failed to respond to doripenem and tobramycin. Ciprofloxacin has been successfully used in Pseudomonas ventriculitis, 6 but our patient's history of anaphylaxis following ofloxacin administration precluded its use.
Meropenem is the only anti-pseudomonal carbapenem approved for the management of CNS infections. The isolate in our patient was initially susceptible to anti-pseudomonal b-lactams, but became resistant after exposure to ceftazidime and meropenem. The isolate from the initial hospital was not available for genetic testing to establish a clonal relationship with the isolates from our hospital, but we suspect that the isolate developed resistance as a result of antibiotic exposure.
Doripenem is a recently approved carbapenem with improved activity against P. aeruginosa. 7 Resistance appears less likely to emerge after exposure of P. aeruginosa to doripenem in vitro and possibly in vivo. 7 -9 Combining doripenem with an aminoglycoside may delay emergence of resistance.
10
P. aeruginosa isolates resistant to imipenem and meropenem may retain susceptibility to doripenem, as occurred in our patient. 11, 12 Doripenem is currently approved only for intra-abdominal and urinary tract infections with the usual dose of 500 mg iv every 8 h. We chose to use a higher dose of 1 g every 8 h to approximate serum concentrations achieved with meropenem. 7 Carbapenems are recognized to have potential neurotoxicity, especially when used in patients with neurological disorders and in high doses. Based on animal models and the results of clinical trials, doripenem may be less epileptogenic than other carbapenems. 7, 13 No neurotoxicity was observed in our patient. With antimicrobial resistance limiting therapeutic options, treatment of CNS infections may increasingly leave clinicians in a therapeutic quandary. Additional future reports of clinical experiences in these situations will be helpful and may aid healthcare provides in decision making.
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